Jumonji is a potential regulatory factor mediating nitric oxide-induced modulation of cardiac hypertrophy

Journal of Cardiovascular Medicine

Volumn 10, Issue 2, 2009, Pages 206-211

  Rabkin, Simon W ^a   Klassen, Shaun S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Jumonji; Left ventricular hypertrophy; Nitric oxide

Indexed keywords

CYCLIN D; JUMONJI PROTEIN; NITRIC OXIDE; PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; CYCLINE; JMJD2A PROTEIN, HUMAN; N DEMETHYLASE;

CELL CYCLE REGULATION; CELL GROWTH; GENE EXPRESSION; HEART DEVELOPMENT; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; UPREGULATION; ANIMAL; ARTICLE; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CYCLINS; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; NITRIC OXIDE; OXIDOREDUCTASES, N-DEMETHYLATING; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION;

EID: 65549100685     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283212ecd     Document Type: Review

References (69)

1. Krauser DG, Devereux RB. Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz 2006; 31:305-316.
2. Meijs MF, de Windt LJ, de Jonge N, Cramer MJ, Bots ML, Mali WP, et al. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 2007; 14:157-171. (Pubitemid 46043911)
3. Takeuchi T, Yamazaki Y, Katoh-Fukui Y, Tsuchiya R, Kondo S, Motoyama J, et al. Gene trap capture of a novel mouse gene, jumonji, required for neural tube formation. Genes Dev 1995; 9:1211-1222.
4. Kortschak RD, Tucker PW, Saint R. ARID proteins come in from the desert. Trends Biochem Sci 2000; 25:294-299.
5. Balciunas D, Ronne H. Evidence of domain swapping within the jumonji family of transcription factors. Trends Biochem Sci 2000; 25:274-276. (Pubitemid 30333385)
6. Takeuchi T, Watanabe Y, Takano-Shimizu T, Kondo S. Roles of jumonji and jumonji family genes in chromatin regulation and development. Dev Dyn 2006; 235:2449-2459. (Pubitemid 44325259)
7. Kim TG, Kraus JC, Chen J, Lee Y. JUMONJI, a critical factor for cardiac development, functions as a transcriptional repressor. J Biol Chem 2003; 278:42247-42255. (Pubitemid 37310492)
8. Lee Y, Song AJ, Baker R, Micales B, Conway SJ, Lyons GE. Jumonji, a nuclear protein that is necessary for normal heart development. Circ Res 2000; 86:932-938. (Pubitemid 30324304)
9. Matsuoka H, Nakata M, Kohno K, Koga Y, Nomura G, Toshima H, et al. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 1996; 27:14-18. (Pubitemid 26017675)
10. Friberg P, Isgaard J, Wahlander H, Wickman A, Guron G, Adams MA. Cardiac hypertrophy and related growth processes: the role of insulin-like growth factor-I. Blood Press Suppl 1995; 2:22-29.
11. Booz GW, Day JN, Baker KM. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 2002; 34:1443-1453.
12. Frank D, Kuhn C, Brors B, Hanselmann C, Ludde M, Katus HA, et al. Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension 2008; 51:309-318. (Pubitemid 351159944)
13. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7:589-600. (Pubitemid 44325350)
14. Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115:527-537.
15. Lezoualc'h F, Metrich M, Hmitou I, Duquesnes N, Morel E. Small GTPbinding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 2008; 44:623-632.
16. Guinamard R, Bois P. Involvement of transient receptor potential proteins in cardiac hypertrophy. Biochim Biophys Acta 2007; 1772:885-894. (Pubitemid 47176370)
17. Nozato T, Ito H, Tamamori M, Adachi S, Abe S, Marumo F, et al. G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. Jpn Circ J 2000; 64:595-601. (Pubitemid 30671026)
18. Chien R. Signaling mechanisms for the activation of an embryonic gene program during the hypertrophy of cardiac ventricular muscle. Basic Res Cardiol 1992; 87 (Suppl 2):49-58. (Pubitemid 23081257)
19. Busk PK, Bartkova J, Strom CC, Wulf-Andersen L, Hinrichsen R, Christoffersen TE, et al. Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro. Cardiovasc Res 2002; 56:64-75. (Pubitemid 35247803)
20. Tamamori M, Ito H, Hiroe M, Terada Y, Marumo F, Ikeda MA. Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. Am J Physiol 1998; 275:H2036-H2040. (Pubitemid 128731571)
21. Poolman RA, Brooks G. Expressions and activities of cell cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy. J Mol Cell Cardiol 1998; 30:2121-2135. (Pubitemid 28495337)
22. Li JM, Poolman RA, Brooks G. Role of G1 phase cyclins and cyclindependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol 1998; 275:H814-H822. (Pubitemid 28439770)
23. Li JM, Brooks G. Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy. Am J Physiol 1997; 273:H1358-H1367. (Pubitemid 27418836)
24. Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C, et al. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclindependent kinases that associate with cyclin D1. Oncogene 1994; 9:71-79. (Pubitemid 24020935)
25. Motoyama J, Kitajima K, Kojima M, Kondo S, Takeuchi T. Organogenesis of the liver, thymus and spleen is affected in jumonji mutant mice. Mech Dev 1997; 66:27-37. (Pubitemid 27376640)
26. Ferguson KL, Callaghan SM, O'Hare MJ, Park DS, Slack RS. The Rb- CDK4/6 signaling pathway is critical in neural precursor cell cycle regulation. J Biol Chem 2000; 275:33593-33600.
27. Busk PK, Hinrichsen R. Cyclin D in left ventricle hypertrophy. Cell Cycle 2003; 2:91-95.
28. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1 - normal and abnormal functions. Endocrinology 2004; 145:5439-5447. (Pubitemid 39564581)
29. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998; 391:597-601. (Pubitemid 28157603)
30. White RJ. RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol 2005; 6:69-78.
31. Learned RM, Learned TK, Haltiner MM, Tjian RT. Human rRNA transcription is modulated by the coordinate binding of two factors to an upstream control element. Cell 1986; 45:847-857.
32. Hannan KM, Hannan RD, Smith SD, Jefferson LS, Lun M, Rothblum LI. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene 2000; 19:4988-4999. (Pubitemid 30808364)
33. Sutcliffe JE, Brown TR, Allison SJ, Scott PH, White RJ. Retinoblastoma protein disrupts interactions required for RNA polymerase III transcription. Mol Cell Biol 2000; 20:9192-9202.
34. Sadoshima J, Aoki H, Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res 1997; 80:228-241. (Pubitemid 27056986)
35. Backs J, Olson EN. Control of cardiac growth by histone acetylation/ deacetylation. Circ Res 2006; 98:15-24. (Pubitemid 43977219)
36. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110:479-488. (Pubitemid 35232291)
37. Bossuyt J, Helmstadter K, Wu X, Clements-Jewery H, Haworth RS, Avkiran M, et al. Ca2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res 2008; 102:695-702.
38. Kim TG, Chen J, Sadoshima J, Lee Y. Jumonji represses atrial natriuretic factor gene expression by inhibiting transcriptional activities of cardiac transcription factors. Mol Cell Biol 2004; 24:10151-10160. (Pubitemid 39507855)
39. Kim TG, Jung J, Mysliwiec MR, Kang S, Lee Y. Jumonji represses alphacardiac myosin heavy chain expression via inhibiting MEF2 activity. Biochem Biophys Res Commun 2005; 329:544-553. (Pubitemid 40311779)
40. Kolodziejczyk SM, Wang L, Balazsi K, DeRepentigny Y, Kothary R, Megeney LA. MEF2 is upregulated during cardiac hypertrophy and is required for normal postnatal growth of the myocardium. Curr Biol 1999; 9:1203-1206.
41. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65:1053-1061. (Pubitemid 121001693)
42. Jung J, Kim TG, Lyons GE, Kim HR, Lee Y. Jumonji regulates cardiomyocyte proliferation via interaction with retinoblastoma protein. J Biol Chem 2005; 280:30916-30923. (Pubitemid 41291823)
43. Gray SG, Iglesias AH, Lizcano F, Villanueva R, Camelo S, Jingu H, et al. Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J Biol Chem 2005; 280:28507-28518. (Pubitemid 41105751)
44. Wollert KC, Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 2002; 7:317-325. (Pubitemid 35396464)
45. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008; 117:2626-2636.
46. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001; 104:1286-1291. (Pubitemid 32848119)
47. Ritchie RH, Schiebinger RJ, LaPointe MC, Marsh JD. Angiotensin IIinduced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol 1998; 275:H1370-H1374. (Pubitemid 28491899)
48. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101:812-818. (Pubitemid 28096078)
49. El-Helou V,Bel-HadjS,Drapeau J, Clement R,Gosselin H,Calderone A. Nitric oxide-mediated inhibition of DNA synthesis was attenuated in hypertrophied neonatal rat ventricular myocytes. Nitric Oxide 2006; 14:316-326.
50. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMPdependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A 2002; 99:11363-11368. (Pubitemid 34920931)
51. Anand-Srivastava MB, Di Fusco F. Redox modulation of Gi protein expression and adenylyl cyclase signaling: role of nitric oxide. Antioxid Redox Signal 2004; 6:385-392. (Pubitemid 38332596)
52. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11:214-222. (Pubitemid 40321358)
53. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49:241-248. (Pubitemid 46142995)
54. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005; 115:1221-1231. (Pubitemid 40629040)
55. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 2008; 133:978-993. (Pubitemid 351787743)
56. Hou Y, Yang J, Zhao G, Yuan Y. Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway. J Cell Biochem 2004; 93:1203-1209. (Pubitemid 44264133)
57. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc Natl Acad Sci U S A 2001; 98:3583-3588. (Pubitemid 32220888)
58. Klassen S, Rabkin SW. Nitric oxide-induces gene expression of jumonji and retinoblastoma 2 protein while reducing expression of atrial natriuretic peptide precursor type B in cardiomyocytes. Folia Biol 2008; 54:65-70. (Pubitemid 351771476)
59. Toyoda M, Shirato H, Nakajima K, Kojima M, Takahashi M, Kubota M, et al. Jumonji downregulates cardiac cell proliferation by repressing cyclin D1 expression. Dev Cell 2003; 5:85-97. (Pubitemid 36827344)
60. Ohno T, Nakajima K, Kojima M, Toyoda M, Takeuchi T. Modifiers of the jumonji mutation downregulate cyclin D1 expression and cardiac cell proliferation. Biochem Biophys Res Commun 2004; 317:925-929. (Pubitemid 38481460)
61. Ying L, Hofseth AB, Browning DD, Nagarkatti M, Nagarkatti PS, Hofseth LJ. Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res 2007; 67:9286-9293. (Pubitemid 47535917)
62. Radisavljevic Z. Inactivated tumor suppressor Rb by nitric oxide promotes mitosis in human breast cancer cells. J Cell Biochem 2004; 92:1-5.
63. Gu M, Lynch J, Brecher P. Nitric oxide increases p21(Waf1/Cip1) expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k). J Biol Chem 2000; 275:11389-11396. (Pubitemid 30212791)
64. Gardner DG. Natriuretic peptides: markers or modulators of cardiac hypertrophy? Trends Endocrinol Metab 2003; 14:411-416.
65. Ishigai Y, Mori T, Ikeda T, Fukuzawa A, Shibano T, Iglesias AH. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am J Physiol 1997; 273:H2659-H2663. (Pubitemid 127752051)
66. Gao XM, Kiriazis H, Moore XL, Feng XH, Sheppard K, Dart A, et al. Regression of pressure overload-induced left ventricular hypertrophy in mice. Am J Physiol Heart Circ Physiol 2005; 288:H2702-H2707. (Pubitemid 40720648)
67. Watanabe H, Murakami M, Ohba T, Takahashi Y, Ito H. TRP channel and cardiovascular disease. Pharmacol Ther 2008; 118:337-351.
68. Muangmingsuk S, Ingram P, Gupta MP, Arcilla RA, Gupta M. Dexamethasone induced cardiac hypertrophy in newborn rats is accompanied by changes in myosin heavy chain phenotype and gene transcription. Mol Cell Biochem 2000; 209:165-173. (Pubitemid 30451448)
69. Schmitt JP, Semsarian C, Arad M, Gannon J, Ahmad F, Duffy C, et al. Consequences of pressure overload on sarcomere protein mutationinduced hypertrophic cardiomyopathy. Circulation 2003; 108:1133-1138. (Pubitemid 37071526)